Ovarian Cancer Diagnostics Market Forecast, Trend Analysis & Competition Tracking: Global Market insights 2017 to 2022

Published on : Jul-2017 | List of Tables : 241 | List of Figures : 81 | No. of Pages : 170 | Report Code : FACT51MR | Format : ppt pdf Excel Word

Ovarian cancer is developed by uncontrollable growth of cells in ovaries. Made up of three different types of cells, ovaries may develop three different types of tumors. Majority of these tumors are non-cancerous, which can be treated by removing either part of the ovary containing the tumor, or by removing the ovary itself.

The American Cancer Society estimates that approx. 20,000 women will be diagnosed with ovarian cancer in the U.S. and more than 14,000 will lose their lives because of it in 2017 alone. In terms of deaths, this form of cancer ranks fifth and it led to more deaths than any other female reproductive system form of cancer. The chance of a women developing ovarian cancer during her life is 1 in 75 and the chance of her dying is 1 in 100. It is mainly seen in older women above the age of 63 years. Even though the rate at which women have been diagnosed with ovarian cancer has been falling, it is still a public health menace that needs to be tackled effectively. This is where the ovarian cancer diagnostics market can play a crucial role. The global ovarian cancer diagnostics market is predicted to grow with a CAGR of 8.7% and be worth nearly US$ 1 billion in 2022, from less than US$ 640 million in 2017.

Market Taxonomy

Cancer Type

End User

Test Type

Epithelial Tumors

Hospital Associated Labs

CA 125

Germ cell carcinoma tumors

Independent Diagnostic Laboratories

HER 2

Stromal carcinoma tumors

Cancer Research Institutes

BRCA

 

Others

CEA

   

ER & PR

   

KRAS Mutation

   

Others

(Additional information, including cross-sectional data and country-wise analysis & forecast is available in the report)

Epithelial Tumours Segment larger than the other two combined

The Epithelial Tumours Segment is anticipated to grow to almost US $ 880 million by the end of the forecast period and it already accounts for an 11% revenue share in 2017 itself.  North America alone represents almost 2/5th of the market and it should touch US$ 330 million by the end of 2022. The germ cell carcinoma tumours segment is much smaller by comparison and is only poised to be a US$ 50 million market by the end of the five year study. Even the stromal carcinoma tumours segment is marginal at best when contrasted with epithelial tumours in the ovarian cancer diagnostics market. The stromal carcinoma tumours segment is likely to be valued at only US$ 28 million in 2017.

Hospital associated and independent diagnostic labs most vital

The hospital associated lab segment is expected to record a CAGR of 7.8% from 2017-2022 and rise from just under $300 million in 2017 to roughly US$ 440 million in 2022. Independent diagnostic labs are the second most important segment in the ovarian cancer diagnostics market and are estimated to be worth US$ 161 million in 2017. While North America might account for the largest contribution, Europe should record a higher CAGR of 9.5% making it more attractive to target in the long term.

Focus on CA 125 test segment in the ovarian cancer diagnostics market

The CA 125 test segment could be worth roughly US$ 440 million in 2022 and some key stakeholders may decide to focus on this lucrative test over all other available alternatives in the ovarian cancer diagnostics market. However, the HER 2 segment also accounts for a 3.1% revenue share in 2017 and it would be unwise to do so. On the other hand, the BRCA segment in North America alone could grow with a CAGR of 8.3% for the period 2017-2022, making it imperative for companies to hedge their bets in the ovarian cancer diagnostics market.

Competition Tracking

The report has also profiled leading players in the global market for ovarian cancer diagnostics, which include Quest Diagnostics Incorporated, Myriad Genetics Inc., AstraZeneca plc., Epigenomics AG, Illumina, Inc., Bio-Rad Laboratories, Inc., Siemens AG, Thermo Fisher Scientific Inc., Roche Holding AG., and Abbott Laboratories.

Note: The insights mentioned here are of the respective analysts, and do not reflect the position of Fact.MR

Medical organizations as well as leaders in the global pharmaceuticals industry are stepping up their efforts towards development of profound diagnosis for ovarian cancer. Rising number of deaths caused by ovarian cancer is taking a toll on governments as people are demanding precision diagnosis and a cure-all for this terminal disease. In a bid to adapt to the urban rat race, millions of consumers have adopted lifestyles that are stemming the occurrence of ovarian cancer. For public administration authorities, compelling people to avoid such lifestyles is like challenging the status quo. The burden of controlling the incidence of ovarian cancer gets passed on to hospitals & medical research organizations as they strive to develop novel diagnostic and therapeutic procedures.

The report on the global market for ovarian cancer discusses such key factors that govern the economics of ovarian cancer diagnostics across the globe. Some of the key influences for the growth of global ovarian cancer diagnostics market include:

  • rising presence of carcinogenic elements in common consumables
  • surging exposure to toxic substances in factories & industrial settings
  • lack of awareness related to causes, symptoms, and preventive measures for ovarian cancer
  • high healthcare costs, deterring ovarian cancer patients from seeking optimum diagnosis

With growing incidence of ovarian cancer, the future generations will witness a more accessible, affordable, and diagnosis-associated treatment for ovarian cancer. As ovarian cancer research organizations & societies struggle to develop effective medications in tight-budgeted capitals, governments are deploying initiatives that boost the awareness of ovarian cancer.

Need for Premeditated Ovarian Cancer Patient Compliance 

Ovarian cancer patients are often riddled with confusing options for diagnosis. Choosing the right screening test can become a dilemma for the patient and his/her family. Companies manufacturing medical instruments and devices for diagnosis of ovarian cancer are expected to mitigate such difficulties by facilitating a well-laid patient compliance regime.

The global market for ovarian cancer diagnostics is anticipated to witness significant impact from diagnosis-associated patient compliance trials. Positive attitudes of patients towards certain diagnosis alternatives is decisive in changing future undertakings. Prominent diagnostic tools are likely to be replaced with their upgraded variants. The report has highlighted the influence of government undertakings in offering a better compliance for diagnosis of ovarian cancer patients.

Key players in the global ovarian cancer diagnostics market are collaborating with regional health ministries and medical administrators for gauging the impact of therapeutic diagnosis on ovarian cancer patients. Such cooperative efforts are of paramount importance in the global ovarian cancer diagnostics market, where overlooking the plausible aftereffects of diagnostic procedures can cost lives.

Ovarian Cancer diagnostics market – Regional Overview & Competitive Backdrop

A comprehensive section on the regional analysis of global ovarian cancer diagnostics market is included in the report. North America, Europe, Japan, Asia-Pacific excluding Japan (APEJ), Latin America, and Middle East & Africa are key regions into which the expansion of global ovarian cancer diagnostics market is studied. Developed markets with robust healthcare infrastructures are deemed lucrative for patients seeking diagnosis for ovarian cancer. On the other hand, higher resource availability, cheap wages, and lenient manufacturing regulations in developing regions attract the attention of manufacturers of ovarian cancer diagnosis instruments.

In the report, there is an elaborate section on the competitive landscape of global ovarian cancer diagnostics market. This part profiles key players in the global market, which includes leading manufacturers of diagnostic devices and related medical apparatus. The scalability employed in profiling these players includes criteria such as the company’s contribution to global ovarian cancer diagnostics market revenues, recent mergers & acquisitions involving the company, and new product launches. Through this report, companies can also understand the investment standpoint in the global ovarian cancer diagnostics market, which can be further inferred while taking insightful actions.

Research Methodology

Fact.MR is committed to offer unbiased and independent market research solutions to its clients. Each market report of Fact.MR is compiled after months of exhaustive research. We bank on a mix of tried-and-tested and innovative research methodologies to offer the most comprehensive and accurate information. Our main sources of research include,

  • Primary research
  • Secondary research
  • Trade research
  • Focused interviews
  • Social media analysis

Chapter 1. Global Ovarian Cancer Diagnostics Market - Executive Summary. 26

Chapter 2. Global Ovarian Cancer Diagnostics Market Overview. 28
2.1. Introduction. 28
       2.1.1. Global Ovarian Cancer Diagnostics Market Taxonomy. 28
       2.1.2. Global Ovarian Cancer Diagnostics Market Definition. 28
2.2. Global Ovarian Cancer Diagnostics Market Size (US$ Mn) and Forecast, 2012-2022. 28
       2.2.1. Global Ovarian Cancer Diagnostics Market Y-o-Y Growth. 28
2.3. Global Ovarian Cancer Diagnostics Market Dynamics. 29
       2.3.1. Drivers. 29
       2.3.2. Restraints. 29
       2.3.3. Trends. 29
2.4. Supply Chain. 30
2.5. Epidemiology. 30
2.6. List of Distributors. 30
2.7. Average Pricing Analysis. 30
2.8. Regulations. 30
2.9. Key Participants Market Presence (Intensity Map) By Region. 31

Chapter 3. Global Ovarian Cancer Diagnostics Market Analysis and Forecast By Cancer Type. 32
3.1. Global Ovarian Cancer Diagnostics Market Size and Forecast By Cancer Type, 2012-2022. 32
       3.1.1. Epithelial Tumors Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 32
                3.1.1.1. Revenue (US$ Mn) Comparison, By Region. 32
                3.1.1.2. Market Share Comparison, By Region. 34
                3.1.1.3. Y-o-Y growth Comparison, By Region. 34
       3.1.2. Germ cell carcinoma tumors Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 35
                3.1.2.1. Revenue (US$ Mn) Comparison, By Region. 35
                3.1.2.2. Market Share Comparison, By Region. 37
                3.1.2.3. Y-o-Y growth Comparison, By Region. 37
       3.1.3. Stromal carcinoma tumors Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 38
                3.1.3.1. Revenue (US$ Mn) Comparison, By Region. 38
                3.1.3.2. Market Share Comparison, By Region. 40
                3.1.3.3. Y-o-Y growth Comparison, By Region. 40

Chapter 4. Global Ovarian Cancer Diagnostics Market Analysis and Forecast By End User. 42
4.1. Global Ovarian Cancer Diagnostics Market Size and Forecast By End User, 2012-2022. 42
       4.1.1. Hospital Associated Labs Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 42
                4.1.1.1. Revenue (US$ Mn) Comparison, By Region. 42
                4.1.1.2. Market Share Comparison, By Region. 44
                4.1.1.3. Y-o-Y growth Comparison, By Region. 44
       4.1.2. Independent Diagnostic Laboratories Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 45
                4.1.2.1. Revenue (US$ Mn) Comparison, By Region. 45
                4.1.2.2. Market Share Comparison, By Region. 47
                4.1.2.3. Y-o-Y growth Comparison, By Region. 47
       4.1.3. Cancer Research Institutes Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 48
                4.1.3.1. Revenue (US$ Mn) Comparison, By Region. 48
                4.1.3.2. Market Share Comparison, By Region. 50
                4.1.3.3. Y-o-Y growth Comparison, By Region. 50
       4.1.4. Others Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 51
                4.1.4.1. Revenue (US$ Mn) Comparison, By Region. 51
                4.1.4.2. Market Share Comparison, By Region. 53
                4.1.4.3. Y-o-Y growth Comparison, By Region. 53

Chapter 5. Global Ovarian Cancer Diagnostics Market Analysis and Forecast By Test Type. 55
5.1. Global Ovarian Cancer Diagnostics Market Size and Forecast By Test Type, 2012-2022. 55
       5.1.1. CA 125 Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 55
                5.1.1.1. Revenue (US$ Mn) Comparison, By Region. 55
                5.1.1.2. Market Share Comparison, By Region. 56
                5.1.1.3. Y-o-Y growth Comparison, By Region. 57
       5.1.2. HER 2 Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 58
                5.1.2.1. Revenue (US$ Mn) Comparison, By Region. 58
                5.1.2.2. Market Share Comparison, By Region. 59
                5.1.2.3. Y-o-Y growth Comparison, By Region. 60
       5.1.3. BRCA Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 61
                5.1.3.1. Revenue (US$ Mn) Comparison, By Region. 61
                5.1.3.2. Market Share Comparison, By Region. 62
                5.1.3.3. Y-o-Y growth Comparison, By Region. 63
       5.1.4. CEA Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 64
                5.1.4.1. Revenue (US$ Mn) Comparison, By Region. 64
                5.1.4.2. Market Share Comparison, By Region. 65
                5.1.4.3. Y-o-Y growth Comparison, By Region. 66
       5.1.5. ER & PR Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 67
                5.1.5.1. Revenue (US$ Mn) Comparison, By Region. 67
                5.1.5.2. Market Share Comparison, By Region. 68
                5.1.5.3. Y-o-Y growth Comparison, By Region. 69
       5.1.6. KRAS Mutation Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 70
                5.1.6.1. Revenue (US$ Mn) Comparison, By Region. 70
                5.1.6.2. Market Share Comparison, By Region. 71
                5.1.6.3. Y-o-Y growth Comparison, By Region. 72
       5.1.7. Others Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 73
                5.1.7.1. Revenue (US$ Mn) Comparison, By Region. 73
                5.1.7.2. Market Share Comparison, By Region. 74
                5.1.7.3. Y-o-Y growth Comparison, By Region. 75

Chapter 6. Global Ovarian Cancer Diagnostics Market Analysis and Forecast By Region. 76
6.1. Global Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 76
       6.1.1. North America Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 76
                6.1.1.1. Revenue (US$ Mn) Comparison, By Cancer Type. 76
                6.1.1.2. Revenue (US$ Mn) Comparison, By End User. 77
                6.1.1.3. Revenue (US$ Mn) Comparison, By Test Type. 79
       6.1.2. Latin America Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 81
                6.1.2.1. Revenue (US$ Mn) Comparison, By Cancer Type. 81
                6.1.2.2. Revenue (US$ Mn) Comparison, By End User. 82
                6.1.2.3. Revenue (US$ Mn) Comparison, By Test Type. 84
       6.1.3. Europe Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 86
                6.1.3.1. Revenue (US$ Mn) Comparison, By Cancer Type. 86
                6.1.3.2. Revenue (US$ Mn) Comparison, By End User. 87
                6.1.3.3. Revenue (US$ Mn) Comparison, By Test Type. 89
       6.1.4. Japan Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 91
                6.1.4.1. Revenue (US$ Mn) Comparison, By Cancer Type. 91
                6.1.4.2. Revenue (US$ Mn) Comparison, By End User. 92
                6.1.4.3. Revenue (US$ Mn) Comparison, By Test Type. 94
       6.1.5. APEJ Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 96
                6.1.5.1. Revenue (US$ Mn) Comparison, By Cancer Type. 96
                6.1.5.2. Revenue (US$ Mn) Comparison, By End User. 97
                6.1.5.3. Revenue (US$ Mn) Comparison, By Test Type. 99
       6.1.6. MEA Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 101
                6.1.6.1. Revenue (US$ Mn) Comparison, By Cancer Type. 101
                6.1.6.2. Revenue (US$ Mn) Comparison, By End User. 102
                6.1.6.3. Revenue (US$ Mn) Comparison, By Test Type. 104

Chapter 7. North America Ovarian Cancer Diagnostics Market Analysis and Forecast, By Country, 2012-2022. 106
7.1. US Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 106
       7.1.1. Revenue (US$ Mn) Comparison, By Cancer Type. 106
       7.1.2. Revenue (US$ Mn) Comparison, By End User. 106
       7.1.3. Revenue (US$ Mn) Comparison, By Test Type. 107
7.2. Canada Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 108
       7.2.1. Revenue (US$ Mn) Comparison, By Cancer Type. 108
       7.2.2. Revenue (US$ Mn) Comparison, By End User. 109
       7.2.3. Revenue (US$ Mn) Comparison, By Test Type. 110

Chapter 8. Latin America Ovarian Cancer Diagnostics Market Analysis and Forecast, By Country, 2012-2022. 111
8.1. Brazil Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 111
       8.1.1. Revenue (US$ Mn) Comparison, By Cancer Type. 111
       8.1.2. Revenue (US$ Mn) Comparison, By End User. 111
       8.1.3. Revenue (US$ Mn) Comparison, By Test Type. 112
8.2. Mexico Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 113
       8.2.1. Revenue (US$ Mn) Comparison, By Cancer Type. 113
       8.2.2. Revenue (US$ Mn) Comparison, By End User. 114
       8.2.3. Revenue (US$ Mn) Comparison, By Test Type. 115
8.3. Argentina Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 116
       8.3.1. Revenue (US$ Mn) Comparison, By Cancer Type. 116
       8.3.2. Revenue (US$ Mn) Comparison, By End User. 117
       8.3.3. Revenue (US$ Mn) Comparison, By Test Type. 118

Chapter 9. Europe Ovarian Cancer Diagnostics Market Analysis and Forecast, By Country, 2012-2022. 119
9.1. Germany Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 119
       9.1.1. Revenue (US$ Mn) Comparison, By Cancer Type. 119
       9.1.2. Revenue (US$ Mn) Comparison, By End User. 119
       9.1.3. Revenue (US$ Mn) Comparison, By Test Type. 120
9.2. UK Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 121
       9.2.1. Revenue (US$ Mn) Comparison, By Cancer Type. 121
       9.2.2. Revenue (US$ Mn) Comparison, By End User. 122
       9.2.3. Revenue (US$ Mn) Comparison, By Test Type. 123
9.3. France Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 124
       9.3.1. Revenue (US$ Mn) Comparison, By Cancer Type. 124
       9.3.2. Revenue (US$ Mn) Comparison, By End User. 125
       9.3.3. Revenue (US$ Mn) Comparison, By Test Type. 126
9.4. Spain Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 127
       9.4.1. Revenue (US$ Mn) Comparison, By Cancer Type. 127
       9.4.2. Revenue (US$ Mn) Comparison, By End User. 127
       9.4.3. Revenue (US$ Mn) Comparison, By Test Type. 128
9.5. Italy Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 129
       9.5.1. Revenue (US$ Mn) Comparison, By Cancer Type. 129
       9.5.2. Revenue (US$ Mn) Comparison, By End User. 130
       9.5.3. Revenue (US$ Mn) Comparison, By Test Type. 131
9.6. Nordic Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 132
       9.6.1. Revenue (US$ Mn) Comparison, By Cancer Type. 132
       9.6.2. Revenue (US$ Mn) Comparison, By End User. 132
       9.6.3. Revenue (US$ Mn) Comparison, By Test Type. 133

Chapter 10. Japan Ovarian Cancer Diagnostics Market Analysis and Forecast, By Country, 2012-2022. 135
10.1. Japan Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 135
       10.1.1. Revenue (US$ Mn) Comparison, By Cancer Type. 135
       10.1.2. Revenue (US$ Mn) Comparison, By End User. 135
       10.1.3. Revenue (US$ Mn) Comparison, By Test Type. 136

Chapter 11. APEJ Ovarian Cancer Diagnostics Market Analysis and Forecast, By Country, 2012-2022. 138
11.1. China Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 138
       11.1.1. Revenue (US$ Mn) Comparison, By Cancer Type. 138
       11.1.2. Revenue (US$ Mn) Comparison, By End User. 138
       11.1.3. Revenue (US$ Mn) Comparison, By Test Type. 139
11.2. India Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 140
       11.2.1. Revenue (US$ Mn) Comparison, By Cancer Type. 140
       11.2.2. Revenue (US$ Mn) Comparison, By End User. 141
       11.2.3. Revenue (US$ Mn) Comparison, By Test Type. 142
11.3. Malaysia Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 143
       11.3.1. Revenue (US$ Mn) Comparison, By Cancer Type. 143
       11.3.2. Revenue (US$ Mn) Comparison, By End User. 143
       11.3.3. Revenue (US$ Mn) Comparison, By Test Type. 144
11.4. Thailand Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 145
       11.4.1. Revenue (US$ Mn) Comparison, By Cancer Type. 145
       11.4.2. Revenue (US$ Mn) Comparison, By End User. 146
       11.4.3. Revenue (US$ Mn) Comparison, By Test Type. 147
11.5. Singapore Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 148
       11.5.1. Revenue (US$ Mn) Comparison, By Cancer Type. 148
       11.5.2. Revenue (US$ Mn) Comparison, By End User. 148
       11.5.3. . Revenue (US$ Mn) Comparison, By Test Type. 149
11.6. Australia Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 150
       11.6.1. Revenue (US$ Mn) Comparison, By Cancer Type. 150
       11.6.2. Revenue (US$ Mn) Comparison, By End User. 151
       11.6.3. Revenue (US$ Mn) Comparison, By Test Type. 152

Chapter 12. MEA Ovarian Cancer Diagnostics Market Analysis and Forecast, By Country, 2012-2022. 153
12.1. GCC Countries Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 153
       12.1.1. Revenue (US$ Mn) Comparison, By Cancer Type. 153
       12.1.2. .Revenue (US$ Mn) Comparison, By End User. 154
       12.1.3. Revenue (US$ Mn) Comparison, By Test Type. 155
12.2. South Africa Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 156
       12.2.1. Revenue (US$ Mn) Comparison, By Cancer Type. 156
       12.2.2. Revenue (US$ Mn) Comparison, By End User. 156
       12.2.3. . Revenue (US$ Mn) Comparison, By Test Type. 157
12.3. Nigeria Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 158
       12.3.1. Revenue (US$ Mn) Comparison, By Cancer Type. 158
       12.3.2. Revenue (US$ Mn) Comparison, By End User. 159
       12.3.3. Revenue (US$ Mn) Comparison, By Test Type. 160
12.4. Israel Ovarian Cancer Diagnostics Market Size and Forecast, 2012-2022. 161
       12.4.1. Revenue (US$ Mn) Comparison, By Cancer Type. 161
       12.4.2. Revenue (US$ Mn) Comparison, By End User. 161
       12.4.3. Revenue (US$ Mn) Comparison, By Test Type. 162

Chapter 13. Company Profiles. 164
13.1. Abbott Laboratories. 164
       13.1.1. Company Overview. 164
       13.1.2. Product Overview:. 164
       13.1.3. Key Financials:. 165
       13.1.4. SWOT Analysis. 165
       13.1.5. Key Developments. 165
13.2. Roche Holding AG.. 166
       13.2.1. Company Overview. 166
       13.2.2. Product Overview:. 166
       13.2.3. Key Financials:. 167
13.3. Thermo Fisher Scientific Inc.. 168
       13.3.1. Company Overview. 168
       13.3.2. Product Overview:. 168
       13.3.3. Key Financials:. 169
       13.3.4. SWOT Analysis. 169
       13.3.5. Key Developments. 169
13.4. Siemens AG. 170
       13.4.1. Company Overview. 170
       13.4.2. Product Overview:. 170
       13.4.3. Key Financials:. 171
       13.4.4. SWOT Analysis. 171
       13.4.5. Key Developments. 171
13.5. Bio-Rad Laboratories, Inc.. 172
       13.5.1. Company Overview. 172
       13.5.2. Product Overview:. 172
       13.5.3. SWOT Analysis. 173
       13.5.4. Key Developments. 175
13.6. Illumina, Inc.. 176
       13.6.1. Company Overview. 176
       13.6.2. Product Overview:. 176
       13.6.3. Key Financials:. 177
       13.6.4. SWOT Analysis. 177
       13.6.5. Key Development. 177
13.7. Epigenomics AG. 178
       13.7.1. Company Overview. 178
       13.7.2. Product Overview:. 178
       13.7.3. Key Financials. 179
       13.7.4. Key Developments. 179
       13.7.5. SWOT Analysis. 179
13.8. AstraZeneca plc. 184
       13.8.1. Company Overview. 184
       13.8.2. Product Overview:. 184
       13.8.3. Key Financials. 185
       13.8.4. Key Developments. 185
       13.8.5. SWOT Analysis. 185
13.9. Myriad Genetics Inc. 189
       13.9.1. Company Overview. 189
       13.9.2. Product Overview. 189
       13.9.3. Key Financials. 190
       13.9.4. SWOT Analysis. 190
13.10. Quest Diagnostics Incorporated. 194
       13.10.1. Company Overview. 194
       13.10.2. Product Overview. 194
       13.10.3. Key Financials. 195
       13.10.4. SWOT Analysis. 195

Chapter 14. Disclaimer and Contact information. 198

Fact.MR offers custom research services that help clients to get specific research solutions

We are committed towards customer satisfaction and quality service.


Our Clients

Malaysian Cocoa Board
Dunlop International Europe Ltd
Roland Berger
Superior Essex
Commscope
Deloitte

Fact.MR in Media

Ovarian Cancer Diagnostics Market Forecast, Trend Analysis & Competition Tracking: Global Market insights 2017 to 2022